

Search this website

[DONATE](#)

[About Us](#) ▾ [For Scientists](#) ▾ [ALS Resources](#) ▾ [Take Action](#) ▾

Biomarker Consortia: Disease Stratification and Progression

As new therapeutics have begun moving the needle for ALS patients, tracking disease progression and monitoring the effects of drug treatment have become even more important. Biomarkers are needed to stratify patient populations, understand response to therapeutics, and quantify disease progression. We are soliciting proposals from collaborative groups focused on the discovery and development of novel disease progression and stratification biomarkers using any modality.

Ready to start the application process?

[CLICK HERE TO APPLY](#)

[DONATE](#)

[About Us](#) ▾ [For Scientists](#) ▾ [ALS Resources](#) ▾ [Take Action](#) ▾

proposals
July 2024

21, 2024

announced
September
2024

October
2024

What We're Funding

Although all groups studying disease progression biomarkers are eligible to apply, Target ALS is particularly interested in supporting projects that propose the study of:

- » Cryptic exons and cryptic exon-related biomarkers
- » Biomarkers with utility in ongoing or upcoming therapeutic trials
- » Biomarkers for patient population stratification for specific therapeutics (e.g. presence of specific cryptic exons, cognitive involvement, ALS/FTD spectrum)

[DONATE](#)

[About Us](#) ▾ [For Scientists](#) ▾ [ALS Resources](#) ▾ [Take Action](#) ▾

Who Should Apply

DONATE

[About Us](#) ▾ [For Scientists](#) ▾ [ALS Resources](#) ▾ [Take Action](#) ▾

biomarkers. Only collaborative projects will be considered.

- » Collaborative projects for this call comprise groups of 3-5 laboratories working around a common theme or target.
- » All collaborators must provide a copy of the executed agreement between their institutions on data/IP sharing OR provide a document that confirms each Technology Transfer Office has been made aware of the collaborative project and the need to sign a data/IP sharing agreement as part of the **full proposal** submission. NOTE: A fully



[DONATE](#)

[About Us](#) ▾ [For Scientists](#) ▾ [ALS Resources](#) ▾ [Take Action](#) ▾

have at least one investigator from the biotech/pharmaceutical industry

- » A Principal Investigator can only participate in one LOI submission.
- » Principal Investigators who have two or more active competitive grants from Target ALS are not eligible to apply.

What Our Grants Support

- » Funding to cover the following project components:
 - » Researcher salaries and fringe benefits
 - » Lab supplies, materials, and equipment

[DONATE](#)

[About Us](#) ▾ [For Scientists](#) ▾ [ALS Resources](#) ▾ [Take Action](#) ▾

leaders from academia, pharma/biotech, venture capital and other non-profits.

» Grant structure:

- » \$130,000 per lab, per year maximum.
- » The total budget for a collaborative project cannot exceed a maximum of \$500,000 per year.
- » The initial grant will be for a two-year period.
- » The consortium will be eligible to compete for a third year of funding based on a review of updated project goals as well as compelling progress at the end of second year of funding.

Ready to start the application process?

[CLICK HERE TO APPLY](#)

Questions? Don't hesitate to contact us.

DONATE

About Us ▾ **For Scientists** ▾ **ALS Resources** ▾ **Take Action** ▾

Funded
Consortia

Annual Meeting

Privacy Policy Credits

The Target ALS (TALS) website is intended for informational purposes only.
Opinions expressed may not be that of TALS or its employees. For more
information about our digital policies, [click here](#).

© 2023 Target ALS
Foundation, Inc.

Target ALS
Foundation
P.O. Box 1598
New York, NY 10101
(332) 333-4140

Steck Insights WordPress
Consulting